The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
Lana Maria De Souza Lawrence , Amit Shah , Mary Elizabeth Young , Vered Stearns , Fariba Asrari , Deborah Anne Frassica , Theodore N. Tsangaris , John H. Fetting , Julie R. Lange , Lisa K. Jacobs , Lee Myers , Antonio C. Wolff , Richard C. Zellars
Regimen | Patients N=34 | Dose/schedule | Schedule | No. of cycles |
---|---|---|---|---|
Standard AC then P |
2 | A 60 mg/m2 C 600 mg/m2 P 80 mg/m2 |
Q 3 wks Q wk |
4 12 |
Dose dense AC then P |
12 | A 60 mg/m2 C 600 mg/m2 G-CSF P 80 mg/m2 |
Q 2 wks Q wk |
4 12 |
TAC | 1 | T 75 mg/m2 A 50 mg/m2 C 500 mg/m2 |
Q 3 wks | 6 |
TC* | 16 | T 75 mg/m2 C 600 mg/m2 |
Q 3 wks | 4-6 |
TCarboH | 3 | T 75 mg/m2 Carbo AUC6 C#1 H 8mg/kg, then 6mg/kg |
Q 3 wks | 6 |
Abbreviations: C, cyclophosphamide; P, paclitaxel; T, docetaxel (Taxotere); A, doxorubicin (Adriamycin); Carbo, carboplatin; H, trastuzumab (Herceptin); G-CSF, granulocyte colony stimulating factor.
*One patient had 6 cycles of TC, all others had 4 cycles.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Danilo Giffoni M. M. Mata
2023 ASCO Annual Meeting
First Author: Mila Meyer Campos Kraychete
2016 ASCO Annual Meeting
First Author: Joanne Lorraine Blum
First Author: Louis Fehrenbacher